Clarification on Behalf of Taj Pharmaceuticals in Respect of Press Release Dated 26th April, 2016
MUMBAI, May 4, 2016 /PRNewswire/ --
We, Mr. Sudheer Singh (Director) & Shantanu Singh, (GM) Of Taj Pharmaceuticals, Hereby Release the Clarification in Respect of our Press Release Dated 26th April, 2016 Referred Above for Ourselves and on the Behalf of Taj Pharmaceuticals
Taj Pharma Group, a Mumbai-based leading generic pharmaceutical company was accused by Emcure Pharmaceuticals of facilitating the export of a batch of sub-standard anti-cancer injections by using its brand name BICNU. Disposing the intellectual property rights case, Justice Gautam Patel said that it had been agreed that after the restraining order, Emcure would not claim any damages in the present suit for the same cause of action.
We state that this was a dispute between Emcure and Taj Pharmaceuticals; going on in the Honorable High Court of Judicature at Bombay being Civil Suit (L) No.230 of 2016 with Notice of Motion (L) No.871 of 2016 instituted in the original side of Honorable Bombay High Court. Said Suit came to be decreed/disposed vide Judgment & Decree dated 21st April, 2016. Thereafter a press note was issued on PR Newswire on 26th April, 2016 which was incorrect. We therefore do hereby clarify that whatever stated in this press note dated 26th April, 2016 is incorrect; not in consonance with the order and decree of Honorable High Court and therefore unconditionally withdraw the said press note dated 26/4/206 in its entirety along with all the contents there in.
This clarification is issued today i.e. 04/05/2016 as per undertaking given before Honorable High Court today i.e. 04/05/2016.
For more information to the previous press release, please visit, http://www.prnewswire.co.in/news-releases/hc-disposed-copycat-drug-claims-and-all-accusations-dropped-between-emcure-pharmaceuticals-and-taj-pharmaceuticals-577123961.html.
About Taj Pharma Group
Taj Pharma Group is one of the leading generic pharmaceutical company in India. We hold top positions in different established markets and are building a strong presence in many emerging generics markets. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.
Media Contact: Shantanu Singh +91 22 2637 4592 email@example.com Executive Director Taj Pharmaceuticals Ltd.